Loading company…
Yuanqi Pharmaceutical develops drugs using target structure research and artificial intelligence.
Yuanqi Pharmaceutical develops drugs based on target structure research and artificial intelligence, including drugs for GPCR targets. Established in 2020 and based in Suzhou, China, it raised approximately RMB 100 million in angel funding in 2021 from Anlongmed Investment, Bohe Angel Fund, and Kaitai Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in